Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477290 | 0.91 | HRH4 (0.55) | HRH4 | |
| SCHEMBL3476758 | 0.83 | HRH4 (0.50) | HRH4 | |
| SCHEMBL4169743 | 0.80 | HRH4 (0.46) | HRH4GPR119CHEK2PRMT5 | |
| SCHEMBL4166408 | 0.79 | HRH4 (0.48) | HRH4GPR119CHEK2PRMT5 | |
| SCHEMBL3477939 | 0.78 | HRH4 (0.53) | HRH4 | |
| SCHEMBL3475607 | 0.77 | HRH4 (0.54) | HRH4 | |
| SCHEMBL3477072 | 0.76 | FAAH (0.56) | FAAHGPR119WNT3ACETP | |
| SCHEMBL3477458 | 0.76 | HRH4 (0.64) | HRH4 | |
| SCHEMBL3476578 | 0.76 | FAAH (0.55) | FAAHGPR119 | |
| SCHEMBL3475790 | 0.75 | BACE1 (0.41) | HRH4CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885FAAH 611/4885GPR119 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.